Astellas Pharma

ALPMY

Drug Manufacturers - General · Healthcare

Price

$14.95

-0.07 (-0.47%)

Market Cap

$26.81B

Exchange

Other OTC

Winston Score

Winston is happy

A high-quality business with solid fundamentals.

Data as of Aug 27, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Exceptional

Growth

Exceptional

Cash Flow

Exceptional

Stability

Exceptional

Valuation

Good

Dividends

Good

Track this stock — start free trial

Share count falling — buybacks

−2.9% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 1.85B (2022) → 1.80B (2026)

Winston Score History

The full picture

Astellas Pharma is a major Japanese pharmaceutical company that develops and sells prescription drugs. Its key products include Xtandi, a widely used treatment for prostate cancer, and Padcev, a newer cancer drug for bladder cancer. The company focuses on urology, oncology, and transplant medicine, selling its medicines to hospitals, clinics, and pharmacies worldwide.

Astellas makes money by selling branded prescription drugs, with a strong gross margin driven by patent-protected therapies. It is headquartered in Tokyo and operates across Japan, the Americas, Europe, and Asia, making it one of Japan's largest drugmakers by revenue. Xtandi remains a major revenue contributor, but patent expiration risk looms, making the success of newer drugs like Padcev and its broader oncology pipeline critical to sustaining long-term growth.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+41.0% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

-22.8% YoY

YoY Growth Rate

Earnings declining

R&D Spend

¥333.8B/ year

→ Flat (+2% vs prior year)

14.7% of revenue

In line with sector average (18%)

Steady R&D investment year-over-year

Insider Activity

0.1%ownership

Relatively low insider ownership

Cash Position

Cash flow positive

¥442.1B cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Revenue accelerating

Astellas Pharma grew revenue 41% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

75.3%

Premium pricing power — 75.3% gross margin

Profit after running costs

Operating Margin

29.0%

Excellent — 29.0% operating margin

Return on the money invested

ROCE

21.4%

Exceptional — 21.4% return on capital

ROIC between 15% and 25%. Every dollar invested in the business earns 15 to 25 cents back per year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+24.0%

Fast-growing sales (+24.0% YoY)

Profit growth

EPS YoY

+373.2%

Earnings growing fast (+373.2% YoY)

Earnings growing 25%+ a year. The compounder zone.

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

158%

Turns 158% of profit into real cash

Spare cash per sale

FCF Margin

22.8%

Converts sales into free cash efficiently (22.8%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.30

Conservative — low debt load (0.30)

Covers its interest

Interest Cover

38.88x

Comfortably covers interest (38.9x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

11.7x

Attractive valuation — P/E 11.7

P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.

Cheaper or dearer next year

P/E vs Forward

-4.7

SLOWING

Earnings expected to fall — forward P/E higher than today

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend

Dividend Yield

3.39%

Moderate income — 3.39% yield

Standard yield zone for stable dividend payers. A meaningful piece of total return.

Dividend record

Dividend Growth

+4.9%

Dividend growing modestly (4.9% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial